Aktienanalyse zu Aura Biosciences, Inc. (AURA)AURAAura Biosciences, Inc.

Aura Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision therapies for solid tumors that aim to preserve organ function. The Company’s lead candidate, bel-sar (AU-011), is in late-stage development for primary choroidal melanoma and in early-stage development in other ocular oncology indications and bladder cancer. It is developing bel-sar as a potential first-line vision-sparing treatment option for early intervention in small choroidal melanoma and/or indeterminate lesions, avoiding the need for radiotherapy and reducing the risk for metastasis for these patients. Bel-sar is a virus-like drug conjugate (VDC) consisting of a human papillomavirus (HPV)-derived virus-like particle (VLP) and a phthalocyanine dye, a light-activated cytotoxic payload. The Company’s platform is designed to enable the targeting of a broad range of solid tumors using VLP, that can be conjugated with drugs or loaded with nucleic acids to create VDCs. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Aura Biosciences Inc is currently priced at $7.40, which is below the recent analyst price targets of $18 and $17, indicating potential upside. However, the stock has a low RSI of 30.349, suggesting it is oversold, which could mean a short-term rebound is possible. The company reported a widening net loss of $45.64 million in Q2 2026, which raises concerns about its financial health. The main risk is the significant insider selling, which increased by 47284.12% over the last month, indicating potential lack of confidence from insiders.